A cancer ubiquitome landscape identifies metabolic reprogramming as target of Parkin tumor suppression

Bozz District

INTRODUCTION

Tumors universally reprogram their metabolism (1) to engender cellular plasticity, promote adaptation to an unfavorable microenvironment, and facilitate disease progression (2). Mechanistically, this involves aberrant utilization of glycolysis even when oxygen is present, the “Warburg effect” (3), as well as exploitation of anabolic and antioxidant mechanisms maintained by the pentose phosphate pathway (PPP) (4). Mitochondria also play an important role in tumor metabolism (5), and their functions in oxidative bioenergetics (6, 7), redox balance (8), and mitochondrial dynamics (9, 10) contribute

Read the rest

When does your metabolism slow down?

Bozz District

Dr. Gabe Mirkin

Many people believe that they gradually gain weight from their 20s onward because their metabolism gets slower over the years, but now it appears that this is not true (Science, Aug 3, 2021:373(6556):808-812). Close to 6,500 people from 29 countries, ranging in age from infancy to 95 years, were followed for more than 40 years. The researchers found that metabolism (the rate at which a person burns calories) remains stable through adult mid-life, from ages 20 to 60. After age 60 it begins to slow down at a rate of slightly less than one percent

Read the rest

Atavistik Bio secures $60M series A to tackle metabolic diseases, cancers with former Peloton, Blueprint Medicines execs at the helm

Bozz District

Atavistik Bio has been “millions of years” in the making, or so the story goes for the disease pathways that have evolved in that time for the preclinical biotech to match this with its own milllions, $60 million to be exact. 

The Cambridge, Massachusetts-based Atavistik emerged with a series A to tackle metabolic diseases and cancers on Tuesday. At the helm are former Peloton Therapeutics and Blueprint Medicines executives and scientific founders from the Howard Hughes Medical Institute.

RELATED: Merck boosts late-phase cancer pipeline with $1.1B Peloton buy

The financing should last about three years as the biotech works to

Read the rest

Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer

Bozz District

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Atavistik Bio (“Atavistik”, “Company”), a pre-clinical biotechnology company pioneering the identification of metabolite-protein interactions that have the potential to lead to the discovery and development of first-in-class drug candidates powered by distinct allosteric control mechanisms, announced today that the Company had completed a $60 million Series A financing round. The financing was led by The Column Group and joined by Lux Capital, and Nextech Invest, Ltd.

The new financing will support development of Atavastik’s drug discovery platform, and future identification of select drug candidates based on deep knowledge of disease relevant pathways that have evolved over

Read the rest

A controversial diet could help treat a chronic metabolic condition

Bozz District

Until recently, type 2 diabetes has mainly been managed by controlling risk factors — such as high blood pressure, cholesterol, and blood sugar (glucose) levels — usually by prescribing drugs.

But this approach doesn’t address the underlying causes of type 2 diabetes — such as problems with the hormone insulin no longer effectively controlling blood sugar. While taking drugs can help to manage blood sugar levels, it won’t help unpick the biological causes behind type 2 diabetes.

A growing body of research shows that losing weight, either through surgery or dieting, can help address some of the underlying causes

Read the rest